Studio clinico NCT07554339 · Non-small Cell Lung Cancer

Studio clinico NCT07554339 (fase III) risulta «in reclutamento» su ClinicalTrials.gov.

Patologia: Non-small Cell Lung Cancer · Interventi registrati: Calderasib, Durvalumab · Date registrate (fonte): 2026-06-18, 2032-12-15, 2026-04-28, 2026-10-09.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy.

The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.

Fonte: https://clinicaltrials.gov/study/NCT07554339